To the full analysis
Buyback calculator for Ocular Therapeutix
Ocular Therapeutix stock: key metrics
OCULOcular Therapeutix had an operating margin of −521% and a return on invested capital (ROIC) of −36.3% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2012 | 30.0% | −136,710.0% | −140,930.0% |
| 2013 | no data | no data | no data |
| 2014 | 88.2% | −3,509.6% | −3,710.9% |
| 2015 | 81.8% | −2,182.7% | −2,271.3% |
| 2016 | 76.5% | −2,296.0% | −2,369.0% |
| 2017 | 76.2% | −3,220.1% | −3,296.2% |
| 2018 | 76.6% | −2,970.8% | −2,899.1% |
| 2019 | 45.0% | −2,029.9% | −2,043.3% |
| 2020 | 88.0% | −361.1% | −894.3% |
| 2021 | 89.9% | −179.3% | −15.1% |
| 2022 | 91.2% | −152.7% | −138.0% |
| 2023 | 91.0% | −141.0% | −138.1% |
| 2024 | 91.2% | −269.6% | −303.7% |
| 2025 | 87.3% | −521.0% | −513.2% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2012 | 30.2% | −45.7% | −55.7% |
| 2013 | 22.4% | −49.5% | −69.6% |
| 2014 | −48.8% | −46.9% | −36.6% |
| 2015 | −44.4% | −33.8% | −36.0% |
| 2016 | −86.0% | −39.5% | −59.7% |
| 2017 | −100.0% | −84.5% | −100.0% |
| 2018 | −100.0% | −83.8% | −79.0% |
| 2019 | 200.0% | no data | −100.0% |
| 2020 | −100.0% | −32.0% | −59.4% |
| 2021 | −7.4% | −29.2% | −3.2% |
| 2022 | −100.0% | −41.9% | −47.6% |
| 2023 | −88.6% | −38.8% | −32.0% |
| 2024 | −61.4% | −42.8% | −42.3% |
| 2025 | −40.6% | −36.3% | −32.9% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 19 Dec 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.